Ignite Creation Date:
2024-05-06 @ 3:28 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04643457
Status:
COMPLETED
Last Update Posted:
2024-06-28
First Post:
2020-11-19
Brief Title:
A Study to Test the Safety Pharmacokinetics and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
A Phase IIIA Randomized Placebo-Controlled Single-Ascending Dose Part A Participant- and Investigator-Blind and Repeated-Dose Part B Participant- Investigator- and Sponsor-Blind Study to Investigate the Safety Pharmacokinetics and Efficacy of UCB9741 in Healthy Study Participants Part A and in Study Participants With Moderate-to-Severe Atopic Dermatitis Part B
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis Furthermore the clinical efficacy outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-003639-41 | EUDRACT_NUMBER | None | None |